**Sample Patient Letter for NSABP B-40 Patients**

*This letter can be downloaded from the CTSU websites and may be edited and
adapted for use at your institution. Use of this letter is optional.*

January 28, 2019

Re: NSABP B-40: *A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens*

Dear Patient:

You have taken part in the clinical trial NSABP B-40, which is now coming to an end. We would like to take this opportunity to thank you for the contributions that you have made to cancer research. Because of your participation, we have gained more information to help us answer some important scientific questions.

We will no longer be collecting information about you from your doctors and nurses. However, it is important that you continue to see your doctor for regular checkups. Your doctor may have recommendations for tests such as mammograms, gynecologic exams, blood work, or other exams.

If you wish to read about the results of the study you participated in, we have included a reference to an abstract published about this study. This publication can be found at medical libraries. We recommend that you discuss the results of the study with your doctor.

Once again, thank you for your very important contribution to cancer research.

Sincerely,

***(Appropriate Physician and Coordinator)***

**REFERENCES FOR NSABP PROTOCOL B-40 PUBLICATION**

Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med* 2012 Jan 26;366(4):310-20. doi: 10.1056/NEJMoa1111097.

Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. *Lancet Oncol* 2015; 16: 1037–48.

Bear HD, Tang G, Rastogi P, et al. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. *Ann Surg Oncol* 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.